428 related articles for article (PubMed ID: 22588608)
1. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.
Pulley JM; Denny JC; Peterson JF; Bernard GR; Vnencak-Jones CL; Ramirez AH; Delaney JT; Bowton E; Brothers K; Johnson K; Crawford DC; Schildcrout J; Masys DR; Dilks HH; Wilke RA; Clayton EW; Shultz E; Laposata M; McPherson J; Jirjis JN; Roden DM
Clin Pharmacol Ther; 2012 Jul; 92(1):87-95. PubMed ID: 22588608
[TBL] [Abstract][Full Text] [Related]
2. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.
Shuldiner AR; Palmer K; Pakyz RE; Alestock TD; Maloney KA; O'Neill C; Bhatty S; Schub J; Overby CL; Horenstein RB; Pollin TI; Kelemen MD; Beitelshees AL; Robinson SW; Blitzer MG; McArdle PF; Brown L; Jeng LJ; Zhao RY; Ambulos N; Vesely MR
Am J Med Genet C Semin Med Genet; 2014 Mar; 166C(1):76-84. PubMed ID: 24616408
[TBL] [Abstract][Full Text] [Related]
3. A surveillance tool to support quality assurance and research in personalized medicine.
Khan NA; Peterson JF
AMIA Annu Symp Proc; 2011; 2011():701-8. PubMed ID: 22195126
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of clopidogrel: evidence and perspectives.
Yin T; Miyata T
Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
[TBL] [Abstract][Full Text] [Related]
6. Personalized approaches to clopidogrel therapy: are we there yet?
Anderson CD; Biffi A; Greenberg SM; Rosand J
Stroke; 2010 Dec; 41(12):2997-3002. PubMed ID: 21030701
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
Scott SA; Sangkuhl K; Gardner EE; Stein CM; Hulot JS; Johnson JA; Roden DM; Klein TE; Shuldiner AR;
Clin Pharmacol Ther; 2011 Aug; 90(2):328-32. PubMed ID: 21716271
[TBL] [Abstract][Full Text] [Related]
8. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?
Shahin MH; Johnson JA
Curr Opin Cardiol; 2013 May; 28(3):305-14. PubMed ID: 23478884
[TBL] [Abstract][Full Text] [Related]
10. Genetic variability in response to clopidogrel therapy and its clinical implications.
Yukhanyan L; Freynhofer MK; Siller-Matula J; Schrör K; Huber K
Thromb Haemost; 2011 May; 105 Suppl 1():S55-9. PubMed ID: 21479337
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
Peters BJ; Harmsze AM; ten Berg JM; Maitland-van der Zee AH; Tjoeng MM; de Boer A; Deneer VH
Pharmacogenomics; 2011 Feb; 12(2):141-4. PubMed ID: 21332306
[No Abstract] [Full Text] [Related]
12. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
Roberts JD; Wells GA; Le May MR; Labinaz M; Glover C; Froeschl M; Dick A; Marquis JF; O'Brien E; Goncalves S; Druce I; Stewart A; Gollob MH; So DY
Lancet; 2012 May; 379(9827):1705-11. PubMed ID: 22464343
[TBL] [Abstract][Full Text] [Related]
13. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a CYP2C19 genotyping assay for clinical use.
Cervinski MA; Schwab MC; Lefferts JA; Lewis LD; Lebel KA; Tyropolis AM; Pflueger SM; Tsongalis GJ
Am J Clin Pathol; 2013 Feb; 139(2):202-7. PubMed ID: 23355205
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
[TBL] [Abstract][Full Text] [Related]
16. Progress of antiplatelet pharmacogenomics.
Oestreich JH
Curr Drug Targets; 2011 Nov; 12(12):1848-58. PubMed ID: 21718233
[TBL] [Abstract][Full Text] [Related]
17. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy.
Sibbing D; Gebhard D; Koch W; Braun S; Stegherr J; Morath T; Von Beckerath N; Mehilli J; Schömig A; Schuster T; Kastrati A
J Thromb Haemost; 2010 Aug; 8(8):1685-93. PubMed ID: 20492469
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?
ten Berg JM; Deneer VH
Nat Rev Cardiol; 2012 Mar; 9(4):192-4. PubMed ID: 22411289
[No Abstract] [Full Text] [Related]
19. Pharmacogenetics: Point-of-care genetic testing--a new frontier explored.
Barrett PM; Topol EJ
Nat Rev Cardiol; 2012 May; 9(6):315-6. PubMed ID: 22547169
[No Abstract] [Full Text] [Related]
20. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
Price MJ; Tantry US; Gurbel PA
Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
